PER37 Antibody

What is CD37 and why is it a significant target for antibody research?

CD37 (also known as TSPAN26) is a tetraspanin protein primarily expressed on the surface of B cells and other immune cells. It plays critical roles in immune cell function, particularly in B cell proliferation, antibody production, and T cell-B cell interactions. CD37 is considered a significant target in immunology and cancer research due to its involvement in various lymphoid malignancies, particularly B-cell neoplasms .

The protein is encoded by the human CD37 gene (Gene ID: 951) and is characterized as a leukocyte antigen with several synonyms including GP52-40, TSPAN26, and cell differentiation antigen 37 . Understanding CD37's structure and function is essential for researchers developing therapeutic approaches targeting B-cell malignancies and immune disorders.

What is PerCP conjugation and how does it enhance antibody applications?

PerCP (Peridinin-Chlorophyll-Protein Complex) is a fluorescent protein complex derived from dinoflagellates that emits in the red spectrum (approximately 675-680 nm) when excited with a 488 nm laser. PerCP conjugation to antibodies offers several advantages in flow cytometry and immunofluorescence applications:

• Signal stability with minimal photobleaching compared to other fluorophores

• Distinct spectral properties that minimize overlap with FITC and PE, facilitating multicolor analyses

• Good signal-to-noise ratio in most applications

• Compatibility with fixation protocols using paraformaldehyde

When conjugated to antibodies targeting CD37 or other antigens, PerCP provides researchers with a reliable detection method for phenotypic and functional studies of cells expressing these markers .

How should PerCP-conjugated antibodies be stored and handled to maintain optimal performance?

Proper storage and handling of PerCP-conjugated antibodies is critical for maintaining their performance and extending their shelf life. Based on manufacturer recommendations:

• Store PerCP-conjugated antibodies at -20°C in the dark. Aliquot into multiple vials to avoid repeated freeze-thaw cycles that can degrade both the antibody and fluorochrome .

• For storage buffers, PerCP-conjugated antibodies are typically maintained in aqueous buffered solutions containing stabilizers such as BSA (often around 1%), along with preservatives like sodium azide (0.03-0.09%) and cryoprotectants such as glycerol (up to 50%) .

• When working with PerCP-conjugated antibodies:

  • Protect from prolonged light exposure

  • Allow solutions to equilibrate to room temperature before opening

  • Centrifuge briefly before use to collect solution at the bottom of the vial

  • Avoid repeated freezing and thawing

Lyophilized formats of PerCP-conjugated antibodies may have different storage requirements and often need reconstitution in appropriate buffers before use .

What are the optimal experimental conditions for using CD37 antibodies in flow cytometry?

When using CD37 antibodies conjugated with PerCP in flow cytometry, researchers should consider several experimental parameters to obtain reliable and reproducible results:

Optimal Staining Protocol:

• Cell preparation: Ensure single-cell suspensions with >90% viability

• Blocking: Use appropriate blocking buffer (containing 1-5% BSA or serum) for 15-30 minutes before antibody staining

• Antibody concentration: Titrate to determine optimal concentration, typically starting with dilutions in the range of 1:50-200 for PerCP-conjugated antibodies

• Incubation conditions: Stain for 20-30 minutes at 4°C in the dark

• Washing: Perform 2-3 gentle washes with ice-cold buffer

• Controls: Always include appropriate isotype controls (IgG-PerCP) and compensation controls

Instrument Settings:

• Excitation: 488 nm laser

• Emission: 675/20 nm or similar bandpass filter

• PMT voltage: Optimize to place negative population in the first decade of the log scale

• Compensation: Properly compensate against PE and other fluorochromes

Cell fixation with 1-2% paraformaldehyde is generally compatible with PerCP-conjugated antibodies when required for delayed analysis or intracellular staining protocols.

How can researchers effectively validate CD37 antibody specificity?

Validating antibody specificity is crucial for experimental rigor. For CD37 antibodies, a comprehensive validation strategy should include:

• Positive and negative control samples:

  • Cell lines with known CD37 expression (positive: most B-cell lines; negative: epithelial cell lines)

  • Knockout/knockdown systems where CD37 expression is genetically eliminated

  • Primary cells with differential expression (B cells vs. T cells)

• Orthogonal methods validation:

  • Correlation of protein detection across multiple techniques (flow cytometry, Western blot, immunoprecipitation)

  • Comparison with mRNA expression data

  • Confirmation using multiple antibody clones targeting different epitopes

• Blocking experiments:

  • Pre-incubation with recombinant CD37 protein to demonstrate specific binding

  • Peptide competition assays using the immunogen peptide

• Cross-reactivity assessment:

  • Testing on closely related family members (other tetraspanins)

  • Species cross-reactivity verification if making cross-species claims

Remember that validation should be performed for each specific application (flow cytometry, immunohistochemistry, etc.) as antibody performance can vary significantly between applications .

What approaches can resolve conflicting data when using CD37 antibodies?

When faced with conflicting results using CD37 antibodies, researchers should systematically investigate potential sources of discrepancy:

• Antibody-related factors:

  • Clone variability: Different antibody clones may recognize distinct epitopes with varying accessibility

  • Lot-to-lot variation: Compare lot numbers and request validation data from manufacturers

  • Conjugation effects: PerCP conjugation might affect binding to certain epitopes

• Experimental variables:

  • Fixation effects: Some fixation protocols may mask or alter the CD37 epitope

  • Buffer composition: Detergents, calcium chelators, or pH may affect antibody binding

  • Cell preparation method: Different isolation techniques can alter surface protein accessibility

• Biological considerations:

  • CD37 expression levels vary across cell differentiation stages

  • Post-translational modifications may affect antibody recognition

  • Alternative splicing variants may lack specific epitopes

• Reproducibility approach:

  • Implement a multiparametric analysis to corroborate findings

  • Utilize alternative detection methods in parallel

  • Consult published literature for established protocols and expected results

Creating a systematic troubleshooting table that documents all variables across experiments can help identify the source of discrepancies.

How do PerCP-conjugated antibodies compare to other fluorochrome conjugates in multicolor flow cytometry?

When designing multicolor flow cytometry panels that include CD37 detection, understanding the relative advantages and limitations of PerCP compared to other fluorochromes is essential:

When incorporating PerCP-conjugated CD37 antibodies in multicolor panels:

• Reserve PerCP for moderately expressed antigens like CD37

• Avoid combining with tandem dyes that emit in similar ranges (PE-Cy5, PerCP-Cy5.5) without proper compensation

• Utilize the 488 nm laser efficiently by pairing with FITC and PE-conjugated antibodies

• Consider spectral unmixing on newer cytometers to resolve overlapping emissions

What are the recommended protocols for using CD37 antibodies in Western blotting?

For effective detection of CD37 using Western blotting, researchers should follow these methodological recommendations:

Sample Preparation:

• Cell lysis buffer selection is critical for membrane proteins like CD37

  • RIPA buffer with 1% NP-40 or Triton X-100, supplemented with protease inhibitors

  • Avoid harsh detergents that may disrupt tetraspanin structure

• Do not boil samples (heat to 37°C for 30 minutes instead) to prevent aggregation of this multi-pass membrane protein

Electrophoresis and Transfer:

• Use gradient gels (4-12% or 4-20%) for optimal resolution

• For transferring hydrophobic membrane proteins, consider:

  • Semi-dry transfer: 25V for 30 minutes with 20% methanol transfer buffer

  • Wet transfer: 30V overnight at 4°C with 10% methanol transfer buffer and 0.05% SDS

Detection:

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Primary antibody: Dilute CD37 antibodies in the range of 1:300-1:5000 depending on the specific product

• Incubation: Overnight at 4°C with gentle rocking

• Secondary antibody: HRP-conjugated anti-species antibody at 1:5000-1:10000

• Detection: Enhanced chemiluminescence (ECL) systems are suitable

Expected Results:
CD37 typically appears at approximately 40-45 kDa, though glycosylation may result in higher apparent molecular weights. Multiple bands may represent different glycosylation states or splice variants .

How can researchers optimize immunofluorescence protocols using PerCP-conjugated CD37 antibodies?

Optimizing immunofluorescence (IF) protocols for PerCP-conjugated CD37 antibodies requires attention to several key factors:

Fixation and Permeabilization:

• For cell surface CD37 detection:

  • Mild fixation with 2-4% paraformaldehyde (10-15 minutes at room temperature)

  • Minimal or no permeabilization to preserve membrane integrity

• For total CD37 detection:

  • Fix with 4% paraformaldehyde (15-20 minutes)

  • Gentle permeabilization with 0.1-0.2% Triton X-100 or 0.1% saponin

Staining Protocol:

• Blocking: 5-10% normal serum (from secondary antibody species) with 1% BSA for 30-60 minutes

• Primary antibody: Dilute PerCP-conjugated CD37 antibody to 1:50-1:200 in blocking buffer

• Incubation: 1-2 hours at room temperature or overnight at 4°C in humidified chamber

• Washing: 3x5 minutes with PBS containing 0.05% Tween-20

• Counterstaining: DAPI (1-5 μg/ml) for nuclear visualization

• Mounting: Anti-fade mounting medium specifically formulated for fluorescence preservation

Microscopy Considerations:

• Use appropriate filter sets for PerCP detection (excitation: 482 nm, emission: 678 nm)

• Minimize exposure time to prevent photobleaching

• Capture reference images quickly as PerCP is moderately susceptible to photobleaching

• Consider spectral imaging systems for multicolor applications with potential overlap

Controls:

• Include isotype control (rabbit IgG-PerCP) at matching concentration

• Use known CD37-positive and CD37-negative cell types as biological controls

• Implement single-color controls when performing multicolor IF to assess bleed-through

How can CD37 antibodies be utilized in studying lymphoid malignancies?

CD37 antibodies serve as valuable tools in researching lymphoid malignancies due to CD37's differential expression patterns across B-cell development stages and malignant transformations:

Diagnostic Applications:

• Immunophenotyping of B-cell neoplasms:

  • High expression in chronic lymphocytic leukemia (CLL)

  • Variable expression in follicular lymphoma and diffuse large B-cell lymphoma

  • Low/absent expression in multiple myeloma and plasma cell disorders

• Minimal residual disease (MRD) monitoring using multiparameter flow cytometry panels

Research Applications:

• Functional studies: Investigating CD37's role in:

  • B-cell receptor signaling

  • Antibody production and class switching

  • Cell migration and adhesion

  • Apoptosis regulation

• Therapeutic development:

  • Evaluating CD37 as a target for antibody-drug conjugates

  • Assessing CD37-targeted immunotherapies

  • Developing bispecific antibodies incorporating CD37 binding

• Biomarker research:

  • Correlating CD37 expression with clinical outcomes

  • Identifying CD37 expression patterns associated with drug resistance

  • Examining CD37 in conjunction with other prognostic markers

For these applications, researchers should select appropriate antibody clones validated specifically for the relevant techniques (flow cytometry, IHC, etc.) and cell types under investigation .

What are common troubleshooting issues with PerCP-conjugated antibodies and their solutions?

Researchers working with PerCP-conjugated antibodies may encounter several technical challenges. Here are common issues and their solutions:

Low Signal Intensity:

• Issue: Weak fluorescence signal in flow cytometry or microscopy

• Solutions:

  • Increase antibody concentration (verify with titration)

  • Optimize staining conditions (time, temperature, buffer)

  • Verify target expression in positive control samples

  • Check instrument settings (voltages, filters, laser alignment)

  • Ensure sample was protected from light throughout processing

High Background:

• Issue: Non-specific staining reduces signal-to-noise ratio

• Solutions:

  • Increase blocking time/concentration (use 2-5% BSA or serum)

  • Add 10% normal serum from the host species of secondary antibody

  • Filter buffers to remove aggregates

  • Include Fc receptor blocking reagent when working with immune cells

  • Reduce antibody concentration after proper titration

Spectral Overlap:

• Issue: False positive signal due to improper compensation

• Solutions:

  • Use single-stained controls for each fluorochrome

  • Implement proper compensation matrices

  • Consider alternative panel design to minimize spillover

  • Utilize spectral unmixing on capable instruments

Photobleaching:

• Issue: Signal loss during analysis

• Solutions:

  • Minimize exposure time during acquisition

  • Use anti-fade mounting media for microscopy

  • Analyze samples immediately after staining when possible

  • Prepare fresh samples if significant signal loss is observed

How should researchers approach antibody validation when designing new CD37-targeted experiments?

When designing experiments utilizing CD37 antibodies, a comprehensive validation strategy is essential to ensure reliable and reproducible results:

Step 1: Literature and Resource Assessment

• Review published literature for established CD37 antibody clones and applications

• Consult antibody validation databases and repositories

• Evaluate manufacturer validation data critically, looking for:

  • Application-specific validation (not just general claims)

  • Relevant positive and negative controls

  • Quantitative metrics of performance

Step 2: Preliminary Validation

• Test antibodies on known positive and negative controls:

  Cell Type	Expected CD37 Expression	Purpose
  B lymphocytes	High	Positive control
  T lymphocytes	Low/Negative	Negative/low expression control
  Epithelial cells	Negative	Negative control

• Perform antibody titration to determine optimal concentration for each application

• Compare multiple CD37 antibody clones when possible

Step 3: Application-Specific Validation

• For flow cytometry:

  • Compare results with literature-reported expression patterns

  • Block with recombinant CD37 to confirm specificity

  • Use appropriate isotype controls at matching concentrations

• For Western blotting:

  • Verify band size matches expected molecular weight (~40-45 kDa)

  • Include positive and negative control lysates

  • Consider siRNA knockdown or CRISPR knockout validation

• For immunofluorescence:

  • Evaluate subcellular localization (membrane staining expected)

  • Compare staining pattern with published results

  • Perform peptide blocking when possible

Step 4: Orthogonal Validation

• Correlate protein detection with mRNA expression data

• Validate findings using multiple detection methods

• Consider genetic manipulation approaches (overexpression, knockdown)

This structured approach to validation helps eliminate both false positive and false negative results, ensuring the reliability of CD37-targeted research .

What role do CD37 antibodies play in developing immunotherapeutic approaches?

CD37 antibodies have emerged as promising tools in immunotherapeutic development, particularly for B-cell malignancies that are resistant to current CD20-targeted therapies:

Therapeutic Antibody Development:

• Mechanism of action studies:

  • Direct cell death induction via CD37 crosslinking

  • Antibody-dependent cellular cytotoxicity (ADCC)

  • Complement-dependent cytotoxicity (CDC)

  • Antibody-dependent cellular phagocytosis (ADCP)

• Antibody-drug conjugates (ADCs):

  • Payload delivery optimization

  • Internalization kinetics assessment

  • Bystander effect evaluation

• Bispecific antibody development:

  • CD37 x CD3 engagers for T-cell recruitment

  • CD37 x CD47 combinations to enhance phagocytosis

Research considerations when using CD37 antibodies for immunotherapy development:

• Clone selection is critical as different epitopes may induce varying biological effects

• Fc engineering may enhance effector functions

• Antibody format (IgG subclass, fragments, conjugates) significantly impacts biological activity

• Expression heterogeneity across patient samples requires thorough characterization

Researchers using CD37 antibodies in this context should implement multiparametric analyses to fully characterize mechanism of action and potential resistance mechanisms.

How can researchers optimize multiplex imaging using PerCP-conjugated antibodies?

Multiplex imaging with PerCP-conjugated antibodies requires careful optimization to achieve high-quality results with minimal spectral overlap:

Panel Design Considerations:

• Select fluorophores with minimal spectral overlap with PerCP:

  • Good combinations: PerCP + FITC + APC + DAPI

  • Challenging combinations: PerCP + PE-Cy5 (significant overlap)

• Assign PerCP to antigens with:

  • Moderate to high expression

  • Distinct subcellular localization from other targets

  • Biological relevance to research question

Optimization Protocol:

• Single-color controls:

  • Stain separate samples with each individual antibody

  • Acquire images using all filter sets to assess bleed-through

  • Create spectral unmixing matrices if appropriate

• Sequential staining approach:

  • For challenging combinations, consider sequential rather than simultaneous staining

  • Fix after each round if necessary

  • Document photobleaching effect after each imaging round

• Image acquisition settings:

  • Optimize exposure times independently for each channel

  • Capture PerCP images early in sequence due to moderate photobleaching

  • Consider spectral imaging approaches for highly multiplexed panels

Advanced Techniques:

• Combined with cyclic immunofluorescence:

  • Use PerCP-conjugated antibodies in initial round

  • Document complete photobleaching before subsequent rounds

  • Implement registration algorithms to align multiple rounds

• Integration with in situ hybridization:

  • Perform protein detection with PerCP-conjugated antibodies

  • Follow with RNA detection using complementary fluorophores

  • Optimize protocols to maintain both protein and RNA integrity

What considerations are important when designing experiments combining flow cytometry and cell sorting using CD37 antibodies?

When designing experiments that involve both analysis and sorting of CD37-positive cells, researchers should address several critical considerations:

Pre-Sorting Optimization:

• Antibody selection:

  • Ensure antibody clone maintains specificity after conjugation

  • Verify binding is not affected by enzymatic dissociation methods

  • Confirm antibody concentration does not induce signaling or affect viability

• Sample preparation:

  • Use gentle isolation methods to preserve surface epitopes

  • Implement dead cell exclusion (e.g., viability dyes compatible with PerCP)

  • Filter samples immediately before sorting (40-70 μm mesh) to prevent clogs

• Instrument setup:

  • Optimize droplet formation parameters for cell type

  • Ensure proper compensation to prevent sorting incorrect populations

  • Set appropriate sort gates based on clear positive/negative discrimination

Sorting Considerations:

• Sort parameters:

  Parameter	Recommendation	Rationale
  Sort precision	Purity mode	Ensures high purity of CD37+ fraction
  Flow rate	Low-medium	Balances speed with accuracy
  Collection buffer	Culture media + 2-10% serum	Maintains viability
  Collection temperature	4°C	Minimizes antibody internalization

• Post-sort analysis:

  • Verify sort purity with immediate reanalysis of a small aliquot

  • Assess viability impact of sorting process

  • Evaluate potential changes in CD37 expression following sort stress

Downstream Applications:

• Functional assays:

  • Determine if antibody binding affects cell function

  • Include appropriate controls (cells exposed to same conditions without sorting)

  • Allow recovery period (typically 2-24 hours) before functional testing

• Molecular analyses:

  • Assess impact of antibody binding on RNA/protein isolation efficiency

  • Consider antibody internalization effects on subcellular fractionation

  • Document any potential influence on signaling pathway activation

• Long-term culture:

  • Evaluate if antibody binding affects proliferation or differentiation

  • Determine half-life of bound antibody on sorted cells

  • Monitor CD37 re-expression patterns over time